全自动分子诊断系统Molecision® R8的多中心性能评估
该多中心研究评估了新型全自动分子诊断系统Molecision® R8的分析性能、多重检测能力及对不同分析物和样本类型的兼容性。结果显示其批内变异系数≤1.55%,声称检出限下可检出率100%,线性相关系数0.9998;与Sansure和Hybribio系统比较,HBV RNA检测斜率95%CI含1、截距含0,Bland-Altman平均偏倚-0.05 lg IU/mL,CT DNA、UU DNA和NG DNA一致率均超过95%(UU DNA阴性一致率除外)。
要点
- Molecision® R8批内CV≤1.55%,声称LoD下可检出率100%,线性相关系数0.9998。
- 与Sansure系统比较HBV RNA,Passing-Bablok回归斜率95%CI含1、截距含0,平均偏倚-0.05 lg IU/mL。
- 与Hybribio系统比较CT DNA、UU DNA和NG DNA一致率均超过95%,但UU DNA阴性一致率除外。
核心结论
- Molecision® R8在多种分析物和样本类型中验证了优良的分析性能。
- R8与常规临床使用的其他PCR平台高度一致,支持其临床安全性和有效性。
- 样本进结果出的工作流程可进一步提升临床分子实验室的效率。
研究设计与样本
- 多中心评估新型全自动分子诊断系统Molecision® R8的分析性能、多重检测能力及对不同分析物和样本类型的兼容性。
- 依据相应指南评估精密度、检出限(LoD)和线性。
- 将Molecision® R8与Sansure和Hybribio两种市售系统进行方法学比较,每种系统使用四种检测:HBV RNA、CT DNA、UU DNA和NG DNA。
主要发现
- 批内变异系数(CV)≤1.55%,声称LoD下可检出率100%,线性相关系数0.9998。
- HBV RNA比较中,Molecision® R8与Sansure系统Passing-Bablok回归斜率95%CI含1、截距95%CI含0,Bland-Altman平均偏倚-0.05 lg IU/mL。
- R8与Hybribio系统在CT DNA、UU DNA和NG DNA检测中一致率均超过95%,但UU DNA阴性一致率除外。
关键数值与推荐
- 批内CV≤1.55%。
- 声称LoD下可检出率100%。
- 线性相关系数0.9998。
- HBV RNA方法比较:Passing-Bablok回归斜率95%CI含1、截距95%CI含0,Bland-Altman平均偏倚-0.05 lg IU/mL。
- CT DNA、UU DNA和NG DNA与Hybribio系统一致率超过95%,UU DNA阴性一致率除外。
临床怎么用
- Molecision® R8可用于HBV RNA、CT DNA、UU DNA和NG DNA等分子检测,与现有PCR平台结果高度一致。
- 样本进结果出的全自动流程有助于提高临床分子实验室的检测效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the analytical performance of a novel fully-automated molecular diagnostics system Molecision® R8, together with its multiplex testing capability and compatibility with different types of analytes and samples. METHODS: Precision, limit of detection (LoD) and linearity were evaluated based on respective guidelines. Method comparisons were conducted between Molecision® R8 and two commercially available systems Sansure and Hybribio, using four assays for use with each system - hepatitis B virus (HBV) RNA, Chlamydia trachomatis (CT) DNA, Ureaplasma urealyticum (UU) DNA, and Neisseria gonorrhoeae (NG) DNA. RESULTS: Molecision® R8 demonstrated excellent analytical performance: within-lab coefficient of variation (CV) was ≤1.55 %, with 100 % detectable rates at claimed LoD and strong linearity with correlation coefficient of 0.9998. In HBV RNA comparison between Molecision® R8 and Sansure system, the 95 % confidence interval of the slope and the intercept in Passing-Bablok regression contained 1 and 0 respectively, and mean bias was -0.05 lg IU/mL in Bland-Altman analysis. Over 95 % agreement rates were found between R8 and Hybribio system in CT DNA, UU DNA and NG DNA detection, except for the negative agreement rate of UU DNA. CONCLUSIONS: Excellent analytical characteristics were verified in various analyte and sample types for Molecision® R8. Clinical safety and effectiveness of R8 were substantiated by its strong consistency with other polymerase chain reaction (PCR) platforms in routine clinical use. With sample-in-result-out workflow, Molecision® R8 could further improve the efficacy of clinical molecular laboratories.
引用
- Ren Y, Chen C, Wang W, et al. Multicenter evaluation of an innovative fully-automated molecular diagnostics system. Clin Chem Lab Med. 2026. PMID: 42803971. doi:10.1515/cclm-2026-0879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。